Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission

Abdelghani, Kawther Ben; Miladi, S.; Yasmine, M.; Fazaa, A.; Sallemi, Mariem; Souebni, L.; Ouenniche, K.; Kassab, S.; Chékili, S.; Salem, Kamel Ben; Zakraoui, L.; Laatar, A.

doi:10.18295/squmj.9.2021.128

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remission, the endpoint therapeutic purpose, can be evaluated using various composite scores, which cannot properly evaluate underlying structural damage. US examination is the best tool that can accurately assess real remission [ 38 ]. Due to several technical advances, US examination has an important role in the quantification of synovitis, and can provide important information for the diagnosis, monitoring, and management of RA [ 39 ].…”

Section: Introductionmentioning

confidence: 99%

MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients

Boldeanu,

Cristea

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Identifying certain serum biomarkers associated with the degree of rheumatoid arthritis (RA) activity can provide us with a more accurate view of the evolution, prognosis, and future quality of life for these patients. Our aim was to analyze the presence and clinical use of matrix metalloproteinase-13 (MMP-13), along with vascular endothelial growth factor (VEGF) and well-known cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) for patients with RA. We also wanted to identify the possible correlations between MMP-13 and these serological markers, as well as their relationship with disease activity indices, quality of life, and ultrasonographic evaluation. For this purpose, we analyzed serum samples of 34 RA patients and 12 controls. In order to assess serum concentrations for MMP-13, VEGF, TNF-α, and IL-6, we used the enzyme-linked immunosorbent assay (ELISA) technique. Our results concluded that higher levels of MMP-13, VEGF, TNF-α, and IL-6 were present in the serum of RA patients compared to controls, with statistical significance. We furthermore identified moderately positive correlations between VEGF, MMP-13, and disease activity indices, as well as with the ultrasound findings. We also observed that VEGF had the best accuracy (97.80%), for differentiating patients with moderate disease activity. According to the data obtained in our study, that although MMP-13, TNF-α and C-reactive protein (CRP) have the same sensitivity (55.56%), MMP-13 has a better specificity (86.67%) in the diagnosis of patients with DAS28(4v) CRP values corresponding to moderate disease activity. Thus, MMP-13 can be used as a biomarker that can differentiate patients with moderate or low disease activity. VEGF and MMP-13 can be used as additional parameters, along with TNF-α and IL-6, that can provide the clinician a better picture of the inflammatory process, disease activity, and structural damage in patients with RA. Our data can certainly constitute a start point for future research and extended studies with multicenter involvement, to support the selection of individualized and accurate therapeutic management strategies for our patients.

show abstract

Section: Introductionmentioning

confidence: 99%

MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients

Boldeanu,

Cristea

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

The role of ultrasonography in assessing remission in juvenile idiopathic arthritis: a systematic review

et al. 2023

View full text Add to dashboard Cite

Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study

Picchianti Diamanti,

Cattaruzza,

Salemi

et al. 2024

Rheumatol Ther

View full text Add to dashboard Cite

Introduction: Clinical remission is the main target in the management of patients with rheumatoid arthritis (RA). However, several authors found synovitis in patients with RA in clinical remission at ultrasonography (US). Upadacitinib is a selective Janus kinase 1 inhibitor that achieved significantly higher remission rates than adalimumab and abatacept in patients with RA. Here we present the 24-week data of the UPAdacitinib Rheumatoid Arthritis REmission UltraSonography (UPARAREMUS) study. Methods: This is a longitudinal multicenter observational study, enrolling bio-naïve and bio-inadequate responder patients affected by RA. The primary endpoint was the proportion Bruno Laganà and Annamaria Iagnocco contributed equally to the work.

show abstract

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission

Cited by 3 publications

References 23 publications

MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients

MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients

The role of ultrasonography in assessing remission in juvenile idiopathic arthritis: a systematic review

Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study

Contact Info

Product

Resources

About